Titan Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8883147055
USD
1.29
-0.01 (-1.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Sunshine Biopharma, Inc.
Blue Water Biotech, Inc.
Inhibikase Therapeutics, Inc.
Tenax Therapeutics, Inc.
Lexaria Bioscience Corp.
Titan Pharmaceuticals, Inc.
Pulmatrix, Inc.
Oragenics, Inc.
Galera Therapeutics, Inc.
Protagenic Therapeutics, Inc.
Comera Life Sciences Holdings, Inc.

Why is Titan Pharmaceuticals, Inc. ?

Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report

Verdict Report

Icon
No Data Found

Is Titan Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Titan Pharmaceuticals, Inc.
-69.28%
-0.18
443.44%
S&P 500
16.12%
0.77
19.29%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
12.95%
EBIT to Interest (avg)
-11.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
-0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.46%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.64
EV to EBIT
-3.51
EV to EBITDA
-3.51
EV to Capital Employed
9.24
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-263.40%
ROE (Latest)
-143.32%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -2.81 MM

NET PROFIT(HY)

Higher at USD -1.49 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

EPS(Q)

Highest at USD -0.57

-4What is not working for the Company
CASH AND EQV(HY)

Lowest at USD 4.76 MM

OPERATING PROFIT(Q)

Lowest at USD -0.78 MM

PRE-TAX PROFIT(Q)

Lowest at USD -0.8 MM

NET PROFIT(Q)

Lowest at USD -0.8 MM

Here's what is working for Titan Pharmaceuticals, Inc.

Operating Cash Flow
Highest at USD -2.81 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

EPS
Highest at USD -0.57
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Titan Pharmaceuticals, Inc.

Operating Profit
Lowest at USD -0.78 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit
Lowest at USD -0.8 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -0.8 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv
Lowest at USD 4.76 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents